• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Seer Inc.

    5/14/25 4:01:18 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $SEER alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Seer, Inc.

    (Name of Issuer)


    Class A Common Stock, $0.00001 par value per share

    (Title of Class of Securities)


    81578P106

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    81578P106


    1Names of Reporting Persons

    Radoff Family Foundation
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    640,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    640,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    640,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.1 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    81578P106


    1Names of Reporting Persons

    Radoff Bradley Louis
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,615,000.00
    6Shared Voting Power

    640,000.00
    7Sole Dispositive Power

    3,615,000.00
    8Shared Dispositive Power

    640,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,255,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Seer, Inc.
    (b)Address of issuer's principal executive offices:

    3800 Bridge Parkway, Suite 102, Redwood City, California 94065
    Item 2. 
    (a)Name of person filing:

    This statement is filed by The Radoff Family Foundation, a Texas non-profit corporation ("Radoff Foundation"), and Bradley L. Radoff. Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons." Mr. Radoff serves as a director of Radoff Foundation and may be deemed to beneficially own the shares of Class A common stock, $0.00001 par value per share (the "Shares") owned directly by Radoff Foundation. Mr. Radoff also serves as an advisor to a certain donor advised charitable account (the "Charitable Account") and may be deemed to beneficially own the Shares held in the Charitable Account.
    (b)Address or principal business office or, if none, residence:

    The address of the principal office of each of the Reporting Persons is 2727 Kirby Drive, Unit 29L, Houston, Texas 77098.
    (c)Citizenship:

    Radoff Foundation is organized under the laws of the State of Texas and Mr. Radoff is a citizen of the United States of America.
    (d)Title of class of securities:

    Class A Common Stock, $0.00001 par value per share
    (e)CUSIP No.:

    81578P106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of the close of business on March 31, 2025: (i) Radoff Foundation directly owned 640,000 Shares; (ii) 30,000 Shares were held in the Charitable Account; and (iii) Mr. Radoff directly owned 3,585,000 Shares. Mr. Radoff, (i) as a director of Radoff Foundation, may be deemed the beneficial owner of the 640,000 Shares owned by Radoff Foundation, and (ii) as an advisor to the Charitable Account, may be deemed the beneficial owner of the 30,000 Shares held in the Charitable Account, which together with the 3,585,000 Shares he directly owned, constitutes an aggregate of 4,255,000 Shares beneficially owned by Mr. Radoff. The filing of this Schedule 13G shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.
    (b)Percent of class:

    The following percentages are based on 55,737,066 Shares outstanding as of February 26, 2025, which is the total number of Shares outstanding as disclosed in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 3, 2025. As of the close of business on March 31, 2025, (i) Radoff Foundation beneficially owned approximately 1.1% of the outstanding Shares, (ii) approximately 0.05% of the outstanding Shares were held in the Charitable Account and (iii) Mr. Radoff may have been deemed to beneficially own approximately 7.6% of the outstanding Shares.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (ii) Shared power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (iii) Sole power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

     (iv) Shared power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons on February 12, 2025.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Radoff Family Foundation
     
    Signature:/s/ Bradley L. Radoff
    Name/Title:Bradley L. Radoff, Director
    Date:05/14/2025
     
    Radoff Bradley Louis
     
    Signature:/s/ Bradley L. Radoff
    Name/Title:Bradley L. Radoff
    Date:05/14/2025
    Get the next $SEER alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SEER

    DatePrice TargetRatingAnalyst
    7/5/2023$10.00Neutral
    JP Morgan
    1/4/2023$9.00 → $6.50Neutral → Underperform
    BofA Securities
    8/11/2022$20.00 → $12.00Overweight → Neutral
    JP Morgan
    3/1/2022$23.00 → $21.00Equal-Weight
    Morgan Stanley
    2/15/2022$46.00 → $23.00Equal-Weight
    Morgan Stanley
    10/15/2021Outperform
    Cowen
    8/13/2021$55.00 → $50.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SEER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT & CFO Horn David R. sold $14,028 worth of shares (6,760 units at $2.08), decreasing direct ownership by 2% to 443,629 units (SEC Form 4)

      4 - Seer, Inc. (0001726445) (Issuer)

      5/22/25 4:13:53 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • CEO AND CHAIR Farokhzad Omid sold $69,854 worth of shares (33,663 units at $2.08), decreasing direct ownership by 3% to 1,306,060 units (SEC Form 4)

      4 - Seer, Inc. (0001726445) (Issuer)

      5/22/25 4:10:49 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PRESIDENT & CFO Horn David R. covered exercise/tax liability with 26,572 shares, decreasing direct ownership by 6% to 450,389 units (SEC Form 4)

      4 - Seer, Inc. (0001726445) (Issuer)

      2/20/25 4:13:50 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency

      REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteograph® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument—its most advanced solution yet for scalable, high-resolution, mass spec-based proteomics. Seer's newest innovation, debuting at the upcoming American Society for Mass Spectrometry (ASMS) annual conference in Baltimore, MD, overcomes the challenges of large-scale proteomic studies that had been hindered by limited throughput and prohibitive costs. It significantly enhances the flagship Proteograph Product Suit

      5/29/25 7:00:00 AM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

      REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Achieved revenue of $4.2 million for the first quarter of 2025Secured a significant contract with a new customer to run a 10,000-sample study in collaboration with Discovery Life SciencesAccelerated third-party validation of platform through increasing number of customer publications, webinars, preprints and reviewsEnded the quarter with approximately $285 million of cash, cash equivalents and investments "We are proud of our

      5/13/25 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer to Report First Quarter 2025 Financial Results on May 13, 2025

      REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to the

      4/24/25 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Seer Inc.

      DEFA14A - Seer, Inc. (0001726445) (Filer)

      5/28/25 4:21:27 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by Seer Inc.

      DEF 14A - Seer, Inc. (0001726445) (Filer)

      5/28/25 4:19:40 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by Seer Inc.

      SCHEDULE 13G/A - Seer, Inc. (0001726445) (Subject)

      5/14/25 4:01:18 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Seer Inc.

      SC 13G/A - Seer, Inc. (0001726445) (Subject)

      8/2/24 6:33:25 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Seer Inc.

      SC 13G/A - Seer, Inc. (0001726445) (Subject)

      7/8/24 4:32:39 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Seer Inc. (Amendment)

      SC 13G/A - Seer, Inc. (0001726445) (Subject)

      4/10/24 10:06:09 AM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    Financials

    Live finance-specific insights

    See more
    • Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

      REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Achieved revenue of $4.2 million for the first quarter of 2025Secured a significant contract with a new customer to run a 10,000-sample study in collaboration with Discovery Life SciencesAccelerated third-party validation of platform through increasing number of customer publications, webinars, preprints and reviewsEnded the quarter with approximately $285 million of cash, cash equivalents and investments "We are proud of our

      5/13/25 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer to Report First Quarter 2025 Financial Results on May 13, 2025

      REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to the

      4/24/25 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook

      REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Achieved revenue of $4.0 million for the fourth quarter of 2024 and $14.2 million for the full year 2024Shipped 10 instruments during 2024, bringing cumulative instruments shipped to 72 as of December 31, 2024Launched a new product application for the Proteograph XT workflow, specifically designed for cell lysis proteomics, unlocking unprecedented depth in intracellular proteomicsShowcased new findings and a

      2/27/25 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    Leadership Updates

    Live Leadership Updates

    See more
    • Seer Appoints Nicolas Roelofs to its Board of Directors

      REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. "Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome." "I'm excited to work with the Seer team and leverage my experience in the life

      8/14/24 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer Announces Appointment of Scott D. Thomas as Chief Commercial Officer

      REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21, 2022. Mr. Thomas joins Seer from Singular Genomics, where he served as Senior Vice President, Sales and Marketing. Prior to Singular, he spent over two decades with increasing commercial responsibilities within the life sciences industry, including 11 years at Illumina. "I'm thrilled to welcome Scott, whose leadership and breadth of expertise in the commercialization of life sciences tools complements the balance of our talented

      3/16/22 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer Appoints Meeta Gulyani to its Board of Directors

      REDWOOD CITY, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Meeta Gulyani to serve on its Board of Directors. Ms. Gulyani is currently Executive Vice President, Head of Strategy, Business Development and Transformation for the Life Science business of Merck KGaA, Darmstadt, Germany, a global science and technology company, which operates as MilliporeSigma in the U.S. and Canada. "Meeta is a seasoned life sciences and pharma leader with global experience across markets, including Asia, an important market for Seer, and we are really pleased to welcome Me

      11/29/21 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JP Morgan resumed coverage on Seer with a new price target

      JP Morgan resumed coverage of Seer with a rating of Neutral and set a new price target of $10.00

      7/5/23 7:25:16 AM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer downgraded by BofA Securities with a new price target

      BofA Securities downgraded Seer from Neutral to Underperform and set a new price target of $6.50 from $9.00 previously

      1/4/23 9:03:59 AM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer downgraded by JP Morgan with a new price target

      JP Morgan downgraded Seer from Overweight to Neutral and set a new price target of $12.00 from $20.00 previously

      8/11/22 6:17:02 AM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials